The Royal Marsden launches AI radiology platform to revolutionise cancer care
Ella Day | May 27, 2025 | News story | Analytical & Laboratory Services, Market & Product Development, Medical Education, Research and Development | AI, CARPL.ai., Institute of Cancer Research, NTT DATA, National Institute for Health and Care Research, Oncology, The Royal Marsden, oncology, radiology
The Royal Marsden, a world-leading cancer research centre, has launched a large-scale, AI-powered radiology platform designed to accelerate cancer detection and treatment using medical imaging. This marks a major milestone in the application of AI for cancer research.
The technology will develop and evaluate AI algorithms to improve the accuracy of cancer evaluation, including sarcoma, lung, breast, brain and prostate cancers. This intends for faster response times, more accurate diagnoses and treatments that are more targeted.
The platform has been collaboratively developed by NTT DATA, which has built a machine operating platform (MLOps) and offers specialist imaging AI consulting services, and CAPRL.ai, an AI and MLO platform.
In response to growing recognition of the potential of AI to enhance the speed and accuracy of identifying imaging biomarkers, the development of the service was funded by the UK’s National Institute for Health and Care Research, the UK’s largest funder of health research.
It will be used for research at The Royal Marsden and the Institute of Cancer Research, including projects in collaboration with other research teams.
“By working with NTT DATA and CARPL.ai, we’ve created a scalable research environment that allows us to explore the full potential of AI safely and in a way that could one day transform cancer diagnosis and treatment across the NHS,” said Dow-Mu Koh, professor in functional cancer imaging and consultant radiologist in functional imaging at The Royal Marsden.
Tom Winstanley, chief technology officer at NTT DATA UK & Ireland, commented: “This service is a great example of responsible innovation in practice, showing the ethical, secure use of AI in healthcare.”
Ella Day
27/5/25
Related Content
BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer
Bristol Myers Squibb (BMS) has announced that its Opdivo (nivolumab) has been accepted, in combination …
Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer
Astellas Pharma, a pharmaceutical company creating medicines to address unmet medical needs, has announced that …
Cellbyte raises $2.75m to fund pharma drug launch platform
Cellbyte has announced that it has raised $2.75m in seed funding for the streamlining of …
